Iterum Therapeutics
ITRM
ITRM was delisted on the 31st of March, 2026.
44 hedge funds and large institutions have $2.57M invested in Iterum Therapeutics in 2021 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 8 closing their positions.
25% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 8
5% more funds holding
Funds holding: 42 → 44 (+2)
0.01% more ownership
Funds ownership: 0.23% → 0.24% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
26% less capital invested
Capital invested by funds: $3.45M → $2.57M (-$883K)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$587K |
| 2 |
VF
Virtu Financial
New York
|
+$215K |
| 3 |
Jane Street
New York
|
+$61.7K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$42.6K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$27.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$266K |
| 2 |
FNBT
FineMark National Bank & Trust
Fort Myers,
Florida
|
-$168K |
| 3 |
Morgan Stanley
New York
|
-$135K |
| 4 |
Millennium Management
New York
|
-$73K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
-$49.5K |
ITRM Hedge Fund Activity: Q4 2021 in Review
44 institutional investors reported a position in Iterum Therapeutics (ITRM) for Q4 2021, worth a combined $2.57M — down 26% from $3.45M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ITRM positions and 8 closed out — a net gain of 2 holders — while 4 added to existing stakes and 7 trimmed.
The largest buyer was Anson Funds Management, opening a new position worth an estimated $587K. The largest seller was Renaissance Technologies, cutting an estimated $266K.
- 44 institutional investors held Iterum Therapeutics (ITRM) as of Q4 2021, up from 42 in Q3 2021.
- Funds reported $2.57M of Iterum Therapeutics stock for Q4 2021, down 26% quarter-over-quarter.
- 10 funds opened new Iterum Therapeutics positions in Q4 2021 and 8 closed out, a net change of +2 holders.
- The largest Iterum Therapeutics buyer in Q4 2021 was Anson Funds Management, an estimated $587K added.
- The largest Iterum Therapeutics seller in Q4 2021 was Renaissance Technologies, an estimated $266K sold.
Based on aggregated 13F filings for Q4 2021.